Understand the source comparison
Klow Versus TB-500: Migration vs Inflammation Control
TB-500 (Thymosin Beta-4) is a 43-amino-acid peptide that promotes cell migration, differentiation, and angiogenesis through upregulation of actin polymerization and matrix metalloproteinase activity. Its primary research application is in models where cell mig
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- TB-500 (Thymosin Beta-4) is a 43-amino-acid peptide that promotes cell migration, differentiation, and angiogenesis through upregulation of actin polymerization and matrix metalloproteinase activity. Its primary research application is in models where cell migration to the injury site is the rate-limiting factor. Such as myocardial infarction recovery, stroke models, and large-scale tissue trauma. TB-500 essentially tells cells to move toward the injury and start rebuilding.
- Klow compare to other research peptides like TB-500 becomes a question of what process you're trying to control. TB-500 doesn't reduce inflammation. It creates permissive conditions for tissue remodeling, which can actually increase transient inflammation as immune cells and fibroblasts flood the injury site. In acute injury models where rapid cellular infiltration is beneficial, that's exactly what you want. In chronic inflammatory conditions. Ulcerative colitis, psoriasis, chronic dermatitis. That same cellular influx perpetuates the disease.
- A useful comparison: in a corneal injury model, TB-500 accelerates re-epithelialization by promoting epithelial cell migration across the wound bed, reducing healing time by 40–50% compared to control. But if the injury is complicated by chronic inflammation (as in recurrent erosion syndromes), epithelial cells migrate into an inflammatory microenvironment where they undergo apoptosis before completing wound closure. Adding Klow to the protocol suppresses the IL-1β and TNF-α that would otherwise kill migrating epithelial cells, allowing TB-500's migratory signal to complete the repair.
- The half-life of TB-500 is significantly longer than Klow. Approximately 10 days in circulation. Which makes dosing schedules very different. TB-500 is typically administered twice weekly; Klow requires twice-daily dosing in most protocols. That difference in pharmacokinetics alone makes them suited to different experimental designs.